北美癫痫市场预测至 2030 年 - 区域分析 - 按类型（进行性肌阵挛性癫痫、反射性癫痫、全身性癫痫等）、给药途径（口服、肠胃外等）、治疗类型（第一代药物、第二代药物和第三代药物）、年龄组（成人和儿童）和分销渠道（医院药房、零售药房等）
癫痫患病率上升推动北美癫痫市场发展
癫痫，也称为癫痫症，是一种慢性脑部疾病。其特征是反复发作，即身体某一部位或整个身体短暂不自主运动。癫痫发作会改变感觉、行为、意识和肌肉运动。癫痫可能是由于遗传性疾病或后天性脑损伤（如创伤或中风）引起的。根据世界卫生组织 (WHO) 2023 年 2 月发布的数据，癫痫占全球疾病负担的很大一部分，影响着全球近 5000 万人。此外，估计每 1,000 人中有 4-10 人患有活动性癫痫（即需要治疗或持续癫痫发作）。每年有近 500 万人被诊断出患有癫痫。高收入国家估计每年每 100,000 人中有 49 人报告患有癫痫。在低收入和中等收入国家，这一数字可能高达每 100,000 人中有 139 人。癫痫发病率的上升可归因于道路交通伤害和出生相关伤害数量的增加，以及脑囊虫病或疟疾等地方性疾病的风险增加。世卫组织还指出，大约 70% 的癫痫患者可以通过使用药物摆脱癫痫发作。控制癫痫的治疗方法包括抗癫痫药物、特殊饮食（除抗癫痫药物外）和手术；然而，抗癫痫药物治疗是大多数患者的主要治疗方法。因此，全球癫痫患病率的上升推动了市场的增长。
北美癫痫市场概述
北美癫痫市场分为美国、加拿大和墨西哥。该地区的市场增长归因于癫痫患者人数的增加、人口老龄化的增长、该地区癫痫药物领域的持续研发、新产品的监管批准增加以及癫痫药物事故和脑损伤数量的增加。
北美癫痫市场收入及预测至 2030 年（百万美元）
北美癫痫市场细分
北美癫痫市场分为类型、给药途径、治疗类型、年龄组、分销渠道和国家。
根据类型，北美癫痫市场分为进行性肌阵挛性癫痫、反射性癫痫、全身性癫痫和其他。全身性癫痫部分在 2022 年占据最大市场份额。
就给药途径而言，北美癫痫市场分为口服、肠外和其他。口服部分在 2022 年占据最大市场份额。
按治疗类型，北美癫痫市场分为第一代药物、第二代药物和第三代药物。第三代药物细分市场在 2022 年占据了最大的市场份额。
根据年龄组，北美癫痫市场分为成人和儿童。成人细分市场在 2022 年占据了更大的市场份额。
就分销渠道而言，北美癫痫市场分为医院药房、零售药房和其他。医院药房细分市场在 2022 年占据了最大的市场份额。
按国家/地区划分，北美癫痫市场分为美国、加拿大和墨西哥。2022 年，美国占据了北美癫痫市场份额的主导地位。
雅培实验室、辉瑞公司、卫材株式会社、UCB SA、LivaNova Plc、诺华公司、美敦力公司、葛兰素史克公司和 H. Lundbeck AS 是北美癫痫市场的一些领先公司。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels for Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. North America Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - North America Analysis
6.1 North America: Epilepsy Market Overview
7. North America Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. North America Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. North America Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. North America Epilepsy Market - Country Analysis
12.1 North America Epilepsy Market Overview
12.1.1 North America: Epilepsy Market Breakdown- by Country, 2022 and 2030 (%)
12.1.1.1.1 United States: Epilepsy Market Overview
12.1.1.1.2 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.1.3 United States: Epilepsy Market Breakdown, by Type
12.1.1.1.4 United States: Epilepsy Market Breakdown, by Route of Administration
12.1.1.1.5 United States: Epilepsy Market Breakdown, by Treatment Type
12.1.1.1.6 United States: Epilepsy Market Breakdown, by Age Group
12.1.1.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.1.8 Canada: Epilepsy Market Overview
12.1.1.1.9 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.1.10 Canada: Epilepsy Market Breakdown, by Type
12.1.1.1.11 Canada: Epilepsy Market Breakdown, by Route of Administration
12.1.1.1.12 Canada: Epilepsy Market Breakdown, by Treatment Type
12.1.1.1.13 Canada: Epilepsy Market Breakdown, by Age Group
12.1.1.1.14 Canada: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.1.15 Mexico: Epilepsy Market Overview
12.1.1.2 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 Mexico: Epilepsy Market Breakdown, by Type
12.1.1.2.2 Mexico: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 Mexico: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 Mexico: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. North America Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview
Table 11. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 12. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 13. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
Table 14. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
Table 15. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 16. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 17. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 18. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
Table 19. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
Table 20. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 21. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 22. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 23. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Treatment Type
Table 24. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Age Group
Table 25. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 26. Recent Organic Growth Strategies in Epilepsy Market
Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. North America Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. North America: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. North America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Growth Strategies in Epilepsy Market
?
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.